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Abstract Calmidazolium, a caimodulin inhibitor, suppressed in- 
flux of Ca 2÷ through voltage-gated Ca 2+ channels in mouse pan- 
creatic 0-cells. Despite this fact, calmidazolium stimulated insu- 
lin release from/]-cells at basal glucose concentration. This effect 
was not mediated by protein kinase C (PKC), since it persisted 
in PKC-depleted cells. RpCAMPS significantly attenuated the 
calmidazolium-stimulated insulin secretion, indicating that calmi- 
dazolium acts, at least partly, through PKA. The compound also 
stimulated insulin secretion from electropermeabilized 0-cells, 
indicating effects on distal steps in the stimulus-secretion cou- 
pling. The use of calmidazolium offers possibilities to investigate 
the mechanisms activating exocytosis under conditions where the 
cytoplasmic-free Ca > concentration does not increase. 
Key wor&': Voltage-gated Ca > channel; Calmidazolium: 
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1. Introduction 
In the pancreatic fl-cell, the physiological secretagogue glu- 
cose causes insulin release through a complex mechanism in- 
volving closure of ATP-regulated K + channels, depolarization, 
opening of w~ltage-gated L-type Ca 2+ channels and, thus, in- 
crease in [Ca>], [1,2]. A tight coupling is believed to exist be- 
tween exocytosis of insulin-containing secretory granules and 
an increase in the cytoplasmic-free Ca 2+ concentration, [Ca2*]~. 
Substances that block influx of Ca 2+ into the ,B-cell, e.g. block- 
ers of voltage-gated L-type Ca > channels, can usually be relied 
upon to inhibit hormone secretion [3]. Some compounds,  e.g., 
phorbol  esters, however, are able to promote vigorous insulin 
secretion f iom fl-cells despite only minor  increments in the Ca > 
current [4]. 
Calmidazol ium, which suppressed Ca 2+ influx through volt- 
age-gated L-type Ca 2+ channels in clonal, insul in-producing 
RINm5F-cel ls,  concomitantly inhibited insulin release from 
those cells [5]. However, prel iminary data surprisingly indicated 
that calmidazol ium actually stimulated insulin secretion from 
pancreatic fl-cells isolated from the ob/ob mouse [6]. Calmi- 
dazolium (compound R24571) has been shown to be an inhib- 
itor of the calmodul in-dependent Ca2+-transport ATPase in red 
blood cells [71]. The compound also inhibits activation of brain 
phosphodiesterase by calmodulin, with a 500 x norm higher 
potency than trif luoroperazine [8]. The aim of the present study 
was to clarify whether calmidazolium can be used to promote 
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exocytosis under conditions where [Ca>]i remains unchanged, 
and, if so, the underlying molecular mechanisms. 
2. Materials and methods 
2.1. Chemicals. statistics 
All reagents were of analytical grade and redistilled eionized water 
was used. Bovine serum albumin fraction V, Fura-2/acetoxymethylester 
and calmidazolium were from Sigma. Student's t-test for unpaired ata 
was used throughout the study for determination f statistically signif- 
icant differences between groups. 
2.2. Media 
The medium used for measurements of [Ca>I+ was a HEPES buffer 
(pH 7.4) containing 1.28 mM Ca >, unless otherwise stated, and with 
CI as the sole anion [9]. Bovine serum albumin, at a concentration of
1 mg/ml, was added to the medium. For the studies of permeabilized 
cells a HEPES buffer, pH 7.0+ was used: this contained (in mM) 110 
KCI+ Ill NaC1, 2 KH2PO 4, 1 MgC12 and 0.5 mg/ml of bovine serum 
albumin. This buffer was supplemented with 2 mM ATP and an ATP- 
regenerating system+ consisting of 10 mM phosphocreatine and 20 U 
creatine kinase/ml. The buffer was also supplemented with 5 mM 
EGTA and Ca "+ in appropriate amounts to give the various desired 
Ca :+ concentrations. For the measurements of glucose oxidation and 
utilization and for the measurements of insulin secretion during static 
incubation, a Krebs-Ringer-bicarbonate buffer (pH 7.4) containing 
3 3.3 mM glucose, was used. 
2.3. Anhnals amt preparation o[' ish't celL~ 
Adult obese hyperglycemic mice (gene symbol ob/ob) of both sexes, 
were obtained l¥om a local non-inbred colony and starved overnight. 
The animals were killed by decapitation and the islets isolated by a 
collagenase t chnique [10]. The islets of these mice contain > 90% fl-cells 
[11]. A cell suspension was prepared and washed essentially as previ- 
ously described [12]. The ceils were resuspended in RPMI 1641) culture 
medium (Flow Laboratories, UK), containing I t mM glucose supple- 
mented with 10% fetal bovine serum. 100 1U/ml penicillin, 100/ag/ml 
streptomycin and 60/ag/ml gentamicin. The cell suspension was then 
either plated on coverslips or maintained in suspension by constant 
agitation. Islets from male Wistar rats were also isolated by a collage- 
nase technique and were cultured overnight in RPMI 1640 culture 
medium. 
2.4. Measurements ol [ (~'el:+/, 
Cells attached to coverslips were incubated with 1.5/aM of the intra- 
cellular fluorescent Ca 2+ indicator fura-2, in its permeable acetoxymeth- 
ylester form. Ibr 15 min at 37°C. During incubation, cells were also 
exposed to either 5 ¢*M calmidazolium or 0.1% of the calmidazolium 
solvent Me+SO. In addition, calmidazolium or Me,SO was present 
during subsequent experiments. [Ca>]+ was measured in small aggre- 
gales of mouse pancreatic fl-cells plated on coverslips. These measure- 
ments were carried out essentially as previously reported [13], using a 
SPEX fluorolog-2 CM1TI 1I system connected to an inverted micro- 
scope (Zeiss, Axiovert 35M). Conversion of fluorescence values to 
[Ca>]i was made according to a previously described equation [14]. 
2.5. Patch-clamp e+~periments 
Subsequent to culture for 24 h, cells were washed with a solution 
composed as follows (mM): choline-Cl (138). KCI (5.6), MgCI: (1.2), 
CaCI_~ [10], tetraethylammonium-chloridc [10], HEPES [5] at pH 7.4. 
Cells were co\ered with 350 pl of the described solution and treated 
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with 5 /.tM calmidazolium for at least 15 min at 37°C. The same 
amount of Me2SO was added to the control dishes. The pipette solution 
contained (mM): N-methyl-D-glucamine (NMDG) (150), HCI (110), 
MgC12 [1], CaCI 2 [2], EGTA [10], Mg-ATP [3], HEPES [5] at pH 7.15. 
All experiments were performed at room temperature (22-24°C). 
NMDG was substituted for K + in the pipette solution, in order to block 
outward directed K + currents. Likewise, choline-Cl was substituted for 
NaCI in the extracellular medium, in order to block inward directed 
Na ÷ currents. The whole-cell configuration of the patch-clamp tech- 
nique [15] was used, utilizing an Axopatch 200 patch-clamp amplifier 
(Axon Instruments, Foster City, CA). Voltage-steps were generated, 
digitized and stored in a computer (IBM AT-clone), using the program 
pClamp (Axon Instruments) and Labmaster ADC (Scientific Solutions, 
Solon, OH). The current responses were filtered at 1 kHz, Bessel filter 
( -3  dB point). The pulse protocol is given in the figure legend. 
2.6. Measurements of glucose oxidation and glucose utilization 
Islets from ob/ob mice were incubated in Krebs-Ringer-bicarbonate 
buffer containing radioactively abelled glucose ([5-3H]glucose and [U- 
~4C]glucose) purchased from New England Nuclear (Boston, MA). In 
order to determine glucose oxidation and utilization in the same indi- 
vidual experiment, we incubated the islets in the presence of both 3H- 
and ~4C-labelled glucose. The islets were incubated in 100/~1 of medium 
containing the labelled glucose and for each group of islets a second vial 
containing 100 ¢tl of identical medium was incubated without islets and 
used to estimate background yield of 3H20 and '4CO2. Half of the islets 
were exposed to 5 /IM calmidazolium and half to a corresponding 
amount of Me2SO as control. Each vial was placed inside a scintillation 
bottle and the bottle was gassed with 95% 02 : 5% CO2 and then sealed. 
The incubations were done in triplicate, each with 20 islets. After incu- 
bation for 60 rain at 37°C, 100/11 of 10% perchloric acid was injected 
into the vials, in order to stop cellular metabolism. 500 pl Hyamine and 
500 pl H:O were injected into the scintillation bottles to absorb ~4CO2 
and 3H20. After overnight incubation, the incubation vials were re- 
moved from the scintillation bottles and 5 ml scintillation fluid was 
added into the bottle, which was then counted for radioactivity in a 
3H/14C channel. The utilization and oxidation of glucose were measured 
from the yield of 3H20 and t4CO2, respectively. 
2. 7. Measurements of insulin release 
Kinetics of insulin release were evaluated by perifusing dispersed 
fl-cells or intact mouse islets mixed with Bio-Gel P4 polyacrylamide 
beads (Bio-Rad) in a 0.5-ml column at 37°C [16,17]. The flow rate was 
~ 250,ul/min and 2-min fractions were collected and analysed for insulin 
radioimmunologically, using crystalline rat insulin as a reference. Insu- 
lin release from permeabilized cells was studied essentially as in Nilsson 
et al. [1 l]. Briefly, cells were added to solutions of specified Ca 2+ concen- 
trations containing the test substance. The Ca 2+ concentrations were 
checked before the experiments with a CaZ+-sensitive mini-electrode. 
Permeabilized cells were incubated uring gentle agitation for 30 rain 
at 37°C. After incubation, cell suspensions were centrifuged and sam- 
ples were taken from the supernatant and assayed for insulin. 
Insulin release from intact islets from male Wistar rats was studied 
using static incubation of groups of 3 islets for 1 h in the presence or 
absence of calmidazolium. 
3.  Resu l ts  
3.1. Measurements of  [Cae+]i 
When mouse fl-cells were st imulated with 25 mM KC1, in the 
presence o f  Me2SO (0.1%) only, there was a large increase in 
[Ca2+]i but, when the exper iments  were per formed in the pres- 
ence o f  5/~M calmidazol ium, the increase in [Ca2+]i was signif- 
icantly at tenuated (Fig. 1A). 
3.2. Patch-clamp experiments 
To investigate if the decrease in depolar izat ion- induced le- 
vat ion in [Ca2+]i was due to direct inhibit ion of  the Ca 2÷ current  
th rough voltage-gated L-type Ca 2+ channels,  patch-c lamp re- 
cordings were per formed.  As exemplif ied in Fig. 1B, pretreat-  
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Fig. 1. Effect of calmidazolium on depolarization-induced increases in 
[Ca2+]~ measured with fura-2 and on Ca 2+ currents, registered with the 
patch-clamp technique. (A) Mouse fl-cell aggregates were stimulated 
with 25 mM KCI in the presence of 3 mM glucose and [Ca2+]~ was 
monitored. Results are expressed as average 340/380-ratio f r the first 
180 s after stimulation. This average value was obtained by using the 
analysis feature of the SPEX Cation Measurement program to calculate 
the 'area under the curve' for these 180 s and dividing by 180. Mean 
values + S.E.M. *P < 0.05. (1) Control experiments performed in the 
presence of 0.1% Me2SO (7 experiments performed on 4 different cell 
preparations). (2) Experiments performed in the presence of 5 pM 
calmidazolium (7 experiments performed on three different cell prepa- 
rations). (B) The whole-cell configuration of the patch-clamp technique 
was established ~ 1 min before starting the pulse protocol. Current races 
from control (Me2SO) and calmidazolium-treated fl-cells. The depolar- 
izing steps were evoked to the membrane potentials indicated in the 
figure, from a holding potential of - 70 mV. (C) Compiled data of the 
I V relationship. Open circles represent calmidazolium-treated cells 
and filled circles represent control cells. To compensate for variation 
in cell size, currents are expressed as current densities (l/C), which were 
obtained by normalizing the current amplitude (1) to cell capacitance 
(C). Mean values + S.E.M., n = 16 for calmidazolium-treated c lls and 
n = 22 for control cells. Results from at least three different prepara- 
tions offl-cells. *P < 0.05, **P < 0.01 and ***P < 0.001. 
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ment offl-cells (for 15 rain) with 5/aM of calmidazolium re- 
sulted in a clear-cut decrease in whole-cell Ca 2÷ currents (only 
falling part of I -V relationship shown). The effect of calmi- 
dazolium was most pronounced atvoltages around 0 mV (Fig. 
1C). 
3.3. Measurements o f  insulin reh'ase 
Since normal ,8-cells displayed a decreased influx of Ca -'+ 
through voltage-gated Ca 2+ channels in the presence of calmi- 
dazolium, it is logical to assume that this effect should be 
parallelled by inhibition of insulin release, as indeed was found 
to be the case in clonal insulin-producing RINm5F-cells [5]. 
However, 8-cells treated with calmidazolium had an average 
basal insulin secretion that was 21 x higher than that from 
control fl-cells (data not shown). [n this context, it should be 
kept in mind, that basal [Ca2+], in the calmidazolium-treated 
cells was not significantly different from that in control cells 
(42 +_ 9 vs. 49 _+ l 1 nM, n = 3 and 4, respectively). Since the 
,8-cell suspension was divided into two equal portions just prior 
to the perifusion experiment, the cell number in the two groups 
should be similar and can not explain the great difference in 
basal insulin secretion. Experiments were also performed to 
investigate if calmidazolium activates insulin secretion from 
,8-cells in the more physiological framework of the intact pan- 
creatic islet. It was demonstrated that calmidazolium signifi- 
cantly stimulated insulin release (250 + 55% above average 
basal secretion, n = 5, P < 0.01) at basal glucose in intact pan- 
creatic islets from ob/ob-mouse. Also, in experiments on intact 
islets from male Wistar rats, 5/aM calmidazolium significantly 
stimulated insulin secretion at basal glucose (38.5 + 1.8 /aU/ 
islet/h [calmidazolium group] compared with 14.5 /aU/islet/h 
[control group], n = 3, P < 0.05). 
Since PKC activation with phorbol ester causes a substantial 
stimulation of insulin secretion even at basal glucose levels [18], 
it was investigated whether calmidazolium stimulation of insu- 
lin release is mediated by PKC. Suspensions of,8-cells from 
ob/ob-mouse were treated for 24 h with 200 nM TPA, in order 
to downregulate protein kinase C (PKC) activity [18], or with 
0.1% Me,SO as control. The cell suspensions were then stimu- 
lated by 5/aM calmidazolium for 10 rain. There was no differ- 
ence in insulin secretion in the PKC-downregulated group, 
compared with the control group (data not shown), speaking 
against PKC as the mediator of the calmidazolium effect. Phor- 
bol ester-stimulated insulin release from ,8-cells is markedly 
potentiated by prior glucose stimulation [18]. Experiments were 
performed to study if the calmidazolium-induced insulin secre- 
tion could be potentiated by initial glucose stimulation. It was 
found that the relative insulin secretion caused by calmi- 
dazolium was unaffected by prior exposure of the ,6-cells to 
glucose (Fig. 2A,B), again suggesting that calmidazolium is 
stimulating hormone release through other mechanisms than 
those activated by phorbol ester. The calmidazolium effect was 
partially reversible during the 18 min of observation after cessa- 
tion of calmidazolium stimulation (Fig. 2A,B). 
Since calmidazolium potently stimulated insulin release from 
intact fl-cells, without increasing [Ca2+]~, it was of interest o 
study if the compound also caused insulin secretion from per- 
meabilized ,8-cells. In such cells, the plasma membrane electri- 
cal potential is short-circuited and rapid equilibration of ions 
and small molecules occurs. Cellular organelles and microtubu- 
lar-microfilamentous structures, however, are left intact. As is 
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Fig. 2. Effect of glucose on subsequent calmidazolium stimulation of 
insulin release from mouse fl-cell suspensions. This figure also shows 
the effect of calmidazolium withdrawal. (A) 5 yM calmidazolium is 
added in the presence of3 mM glucose. (B)fl-cells are first stimulated 
with 20 mM glucose and then with 5 pM calmidazolium. Average 
insulin release during the first 10 min was taken as 100% and all values 
are given relative to this. Mean values + S.E.M. (n = 3 4). 
shown in Fig. 3, 5/aM calmidazolium significantly increased 
insulin release (B) compared with control experiments (A) in 
permeabilized,8-cells incubated in buffers where the Ca 2+ con- 
centration was clamped to 100 nM. Cells incubated in a buffer 
containing 10 nM TPA and 100/aM Ca -'+, which potently stim- 
ulates insulin secretion, were used as a positive control of the 
experimental system (C). 
In order to evaluate ifcalmidazolium was stimulating insulin 
release by interacting with the PKA-signalling system, fl-cells 
were treated with RpCAMPS, an inhibitor of PKA [19]. As is 
demonstrated in Fig. 4, after 20 min of calmidazolium stimula- 
tion, it was found that in,8-cells treated with RpcAMPS, insulin 
release was stimulated by 865 + 174% (A) compared with 
2274 + 561% (B) in the control group. The difference isstatisti- 
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Fig. 3. Effects of calmidazolium and TPA+high Ca 2÷ on insulin release 
from permeabilized mouse fl-cells. Results are indicated by vertical 
bars. (A) Control cells incubated inbuffer containing 0.1% Me2SO and 
100 nM Ca 2+. (B) Cells incubated in a buffer containing 5 ,uM calmi- 
dazolium and 100 nM Ca -'+. (C) Cells incubated ina buffer containing 
10 nM TPA and 100yM Ca -'+, as a positive control of the experimental 
system. Average insulin release in the Me_,SO control group in each 
experiment was taken as 100% and insulin release in all groups was then 
normalized with respect to this average secretion. Mean val- 
ues _+ S.E.M. Statistical significances were calculated using Student's t 
test for unpaired ata, applying the Bonferroni correction for multiple 
comparisons. *P < 0.01 (n = 6, three different cell preparations). When 
evaluating statistical significances, groups B and C were compared with 
the control group A. 
cally significant (P < 0.05) and suggests that the stimulatory 
effect of calmidazolium is at least in part mediated by the 
cAMP-PKA system. 
3.4. Measurements ofglucose oxidation and glucose utilization 
In order to exclude unspecific toxic actions of calmidazolium 
on the fl-cell, the effect of the compound on glucose oxidation 
and utilization was measured. Glucose oxidation was 12.6 + 1.9 
pmol/islet/h in islets exposed to 5/~M calmidazolium compared 
with 10.9 + 1.4 pmol/islet/h in control islets. Glucose utilization 
was 83.3+8.0 pmol/islet/h (calmidazolium group) and 
73.5 + 5.7 pmol/islet/h (control group). The differences be- 
tween calmidazolium-treated and control islets regarding the 
two aspects of glucose metabolism were not statistically signif- 
icant. Exclusion of Trypan blue was the same in calmidazolium- 
treated fl-cells as in control cells (data not shown). 
4. Discussion 
We demonstrate that influx of Ca > through voltage-gated 
L-type Ca 2÷ channels in mouse pancreatic fl-cells is attenuated 
by calmidazolium. This was evident both from direct measure- 
ments of voltage-gated caa+-channel activity and changes in 
[Ca2+]~ in response to K ÷ depolarization. The results are in 
accordance with previously published data by Safayihi et al. 
[20], Li et al. [21] and Kindmark et al. [5], which showed that 
the calmodulin antagonists CGS9343B [20,21] and calmi- 
dazolium [5] inhibit KCl-induced increases in [Ca2+]i in insulin- 
producing cell lines. Calmidazolium is likely to inhibit not only 
Ca 2+ influx but also outward transport of Ca 2+ by the plasma 
membrane Ca 2+ pump, a calmodulin-dependent zyme [22]. 
This fact could explain why the inhibition of Ca 2+ influx 
through voltage-gated Ca 2+ channels was more pronounced 
(Fig. 1C) than the attenuation of depolarization-induced risein 
[Ca2+]i (Fig. 1A). The latter effect is the net result of both influx 
and extrusion of Ca z+ ions. The mechanism by which calmi- 
dazolium inhibits Ca -'+ flux through voltage-gated Ca 2+ chan- 
nels is not clear. It has, however, been demonstrated that calmi- 
dazolium, at the concentrations used in the present study, 
displaces the Ca2+-channel antagonists nitrendipine and dil- 
tiazem from their binding sites in rat cerebral cortex homoge- 
nate [23]. Thus, calmidazolium could inhibit Ca 2+ influx by 
direct interaction with the channel protein. Furthermore, the 
voltage-gated Ca > channel is a substrate for phosphorylation 
[24] and interference with CaZ+-calmodulin-dependent channel 
protein phosphorylation cannot be ruled out as a mechanism 
for calmidazolium-induced inhibition of Ca 2+ influx. Indeed, in 
a recent study, Ca 2+ currents in smooth muscle cells were en- 
hanced by calmodulin-dependent protein kinase II in a Ca >- 
dependent manner [25]. 
Since influx of Ca 2÷ into normal mouse fl-cells was reduced 
in the presence of calmidazolium, it was of interest o investi- 
gate the effects of the compound on insulin release. Unexpect- 
edly, basal insulin secretion was greatly increased in the pres- 
ence of the compound. It has been demonstrated that 10/~M 
calmidazolium potently stimulates secretion of ATP from 
human platelets [26]. In that study, however, the calmodulin 
antagonist also increased [Ca2+]i and it was suggested that 
calmidazolium could possess ionophoretic properties. With re- 
gard to normal fl-cells, the stimulatory effect of calmidazolium 
on insulin release is unlikely to be caused by unspecific perme- 
abilization of the plasma membrane and consequent leakage of 
hormone to the extracellular space. After 15 min of incubation 
in the presence of calmidazolium, basal [Ca2+]i remained nor- 
mal and exclusion of Trypan blue was the same as in control 
cells. Also speaking against a general toxic effect of calmi- 
dazolium on insulin-producing cells, is the fact that 10 ¢tM of 
the compound id not affect glucose oxidation or utilization in 
the present study, or in RINm5F-cells in a previous tudy [5]. 
The fact that islets from the ob/ob mouse respond with insulin 
secretion during stimulation with a substance, which is a calm- 
odulin antagonist and which blocks voltage-gated Ca 2+ chan- 
nels, is in agreement with previously published ata, showing 
that both the calmodulin antagonist rifluoroperazine and 
Ca2+-channel antagonists verapamil and nifedipine stimulate 
insulin release at basal glucose in islets from this animal model 
[27]. However, since calmidazolium also stimulated insulin se- 
cretion in rat islets, this response may be a more general feature 
of normal, differentiated fl-cells. RINm5F-cells are clonal 
tumor cells that exhibit a different stimulus secretion coupling 
than normal fl-cells, which may account for the fact that calmi- 
dazolium has no effect on basal insulin release in this cell line 
[5]. 
Agonists stimulating PKC can induce insulin secretion even 
at basal glucose concentrations [18] and experiments were 
therefore performed to determine if calmidazolium was acting 
through this enzyme. Insulin release in the presence of calmi- 
dazolium was the same in fl-cells, whether subjected to PKC 
downregulation r not. Downregulation leaves a residual PKC 
activity, corresponding to -16% of normal [18], which may be 
part of the calmidazolium-signalling pathway. However, fur- 
ther support for the fact that PKC, at least those isoforms that 
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subsequent calmidazolium stimulation of insulin release. RpcAMPS 
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(n = 5). *P < 0.05. Experiments performed in the presence of 3 mM 
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are sensitive to phorbol  ester, is not involved in the mechanism 
whereby calmidazolium stimulates insulin release is given by 
the results showing that this effect is not potentiated by prior 
glucose stimulation, which is true for TPA-indueed insulin re- 
lease [18]. 
Calmidazol ium-stimulated insulin release is partially inhib- 
itable by RpcAMPS, suggesting that at least some of the insuli- 
notropic effect of calmidazol ium is mediated by the cAMP-  
PKA system. The compound may activate exocytosis either 
through direct interaction with PKA, or by raising the intracel- 
lular cAMP concentration. Calmidazol ium has not been shown 
to interact directly with PKA, but as a calmodulin antagonist, 
calmidazol ium ay interfere with several steps of intracellular 
cAMP metabolism. In this context it is of interest o note that 
calmodulin has been implicated both in the regulation of cAMP 
formation, at the level of adenylate cyclase [28] and cAMP 
breakdown, at the level of cyclic nucleotide phosphodiesterase 
[29]. Hence, it is difficult to forecast he net effect of calmodulin 
inhibit ion on cAMP levels in the cell. Henquin has demon- 
strated that the calmodulin inhibitor trif luoroperazine slightly 
increases islet cell cAMP concentrat ion i the absence of glu- 
cose [30]. A high concentrat ion of the adenylate cyclase activa- 
tor forskolin (20/~M), which increases intracellular cAMP con- 
centrations 60-fold in islet cells, barely doubles insulin release 
at basal glucose [31]. However, in islets from ob/ob mice, 
cAMP-rais ing stimuli elicit a much more pronounced insulin 
release at basal glucose than in islets from lean mice [32]. 
it can again be concluded that an elevated [Ca2+], is not a 
prerequisite for activation of insulin release, a fact previously 
demonstrated for stimulators of PKC [33] and PKA [34]. 
Calmidazol ium activates insulin secretion at resting [Ca>]i and 
although PKA seems to mediate part of the stimulatory effect, 
the complete understanding of calmidazol ium-induced xocy- 
tosis of insulin in normal fl-cells merits further investigations. 
A deeper understanding of the mechanisms involved should 
shed light on the molecular machinery directly regulating ex- 
ocytosis in the pancreatic fl-cell. 
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